Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.

Authors:
Address: Translational Research Division, International Vaccine Institute, Seoul, Republic of Korea. sunghye.kim@post.harvard.edu
Journal:


Publication:

abstract

MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African "meningitis belt". In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri, Niamey, and Dosso, in September and December 2010. We evaluated the campaign and determined which sub-populations or areas had low levels of vaccination Coverage in the regions of Tillabéri and Niamey. after Phase I, conducted in the Filingué district, we estimated coverage using a 30×15 cluster-sampling survey and nested lot quality assurance (LQA) analysis in the clustered samples to identify which subpopulations (defined by age 1-14/15-29 and sex) had unacceptable vaccination coverage (<70%). After Phase II, we used Clustered Lot Quality Assurance Sampling (CLQAS) to assess if any of eight districts in Niamey and Tillabéri had unacceptable vaccination coverage (<75%) and estimated overall coverage. Estimated vaccination coverage was 77.4% (95%CI: 84.6-70.2) as documented by vaccination cards and 85.5% (95% CI: 79.7-91.2) considering verbal history of vaccination for Phase I; 81.5% (95%CI: 86.1-77.0) by card and 93.4% (95% CI: 91.0-95.9) by verbal history for Phase II. Based on vaccination cards, in Filingué, we identified both the male and female adult (age 15-29) subpopulations as not reaching 70% coverage; and we identified three (one in Tillabéri and two in Niamey) out of eight districts as not reaching 75% coverage confirmed by card. Combined use of LQA and cluster sampling was useful to estimate vaccination coverage and to identify pockets with unacceptable levels of coverage (adult population and three districts). Although overall vaccination coverage was satisfactory, we recommend continuing vaccination in the areas or sub-populations with low coverage and reinforcing the social mobilization of the adult population.



Related Articles
Evaluation of immunization coverage by lot quality assurance sampling compared with 30-cluster sampling in a primary health centre in India.
Bull World Health Organ. 1996
Evaluation of immunization coverage by lot quality assurance sampling compared with 30-cluster sampling in a primary health centre in India.
Singh J, Jain DC, Sharma RS, Verghese T. Bull World Health Organ. 1996; 74(3):269-74.
Cluster-sample surveys and lot quality assurance sampling to evaluate yellow fever immunisation coverage following a national campaign, Bolivia, 2007.
Trop Med Int Health. 2009
Cluster-sample surveys and lot quality assurance sampling to evaluate yellow fever immunisation coverage following a national campaign, Bolivia, 2007.
Pezzoli L, Pineda S, Halkyer P, Crespo G, Andrews N, Ronveaux O. Trop Med Int Health. 2009 Mar; 14(3):355-61. Epub 2009 Jan 28.
Clustered lot quality assurance sampling: a tool to monitor immunization coverage rapidly during a national yellow fever and polio vaccination campaign in Cameroon, May 2009.
Epidemiol Infect. 2012
Clustered lot quality assurance sampling: a tool to monitor immunization coverage rapidly during a national yellow fever and polio vaccination campaign in Cameroon, May 2009.
Pezzoli L, Tchio R, Dzossa AD, Ndjomo S, Takeu A, Anya B, Ticha J, Ronveaux O, Lewis RF. Epidemiol Infect. 2012 Jan; 140(1):14-26. Epub 2011 Mar 22.
Review Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.
Cochrane Database Syst Rev. 2005
Review Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.
Patel M, Lee CK. Cochrane Database Syst Rev. 2005 Jan 25; (1):CD001093. Epub 2005 Jan 25.
Review Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
J Manag Care Pharm. 2010
Review Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP. J Manag Care Pharm. 2010 Apr; 16(3):217-30.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.